WHO panel proposes new global registry for all CRISPR human experiments
By Jon Cohen,
Science
| 03. 19. 2019
There’s an “urgent need” to create a transparent global registry that would list all experiments related to human genome editing, an expert committee convened to advise the World Health Organization (WHO) said today. The international committee of 18 researchers and bioethicists, which met in Geneva, Switzerland, over the past 2 days, also agreed with the widespread consensus that it would be “irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.”
The committee stopped short, however, of endorsing the call for a “moratorium” on human germline editing issued last week by prominent group of researchers in a Nature commentary. “I don’t think a vague moratorium is the answer to what needs to be done,” said Margaret Hamburg, a co-chair of the WHO committee who formerly headed the U.S. Food and Drug Administration and now works with the U.S. National Academy of Medicine in Washington, D.C., during a teleconference for the media today. Several other high-profile statements and reports on genome editing have also avoided using the word “moratorium,” although they have similarly emphasized...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...